دورية أكاديمية
Stigma Surrounding the Use of Medically Assisted Treatment for Opioid Use Disorder.
العنوان: | Stigma Surrounding the Use of Medically Assisted Treatment for Opioid Use Disorder. |
---|---|
المؤلفون: | Witte TH; The University of Alabama, Tuscaloosa, AL, USA., Jaiswal J; The University of Alabama, Tuscaloosa, AL, USA., Mumba MN; The University of Alabama, Tuscaloosa, AL, USA., Mugoya GCT; The University of Alabama, Tuscaloosa, AL, USA. |
المصدر: | Substance use & misuse [Subst Use Misuse] 2021; Vol. 56 (10), pp. 1467-1475. Date of Electronic Publication: 2021 Jun 11. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 9602153 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2491 (Electronic) Linking ISSN: 10826084 NLM ISO Abbreviation: Subst Use Misuse Subsets: MEDLINE |
أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: Monticello, NY : Dekker, 1996- |
مواضيع طبية MeSH: | Buprenorphine*/therapeutic use , Opioid-Related Disorders*/drug therapy, Analgesics, Opioid/therapeutic use ; Humans ; Opiate Substitution Treatment ; Social Stigma |
مستخلص: | Purpose: This study sought to determine whether certain factors influenced public stigma toward the use of medication to treat opioid use disorders (MOUD). Method : In a series of 3 studies using between-subjects designs, hypothetical MOUD patients matched in age and educational status with the participants were varied in systematic ways to determine whether certain factors influenced stigmatizing views of the patients. Results : Study 1 ( n = 142) determined that stigma levels were elevated for hypothetical patients receiving agonist medication for OUD compared to other medications or no medication at all. Study 2 ( n = 144) found that hypothetical patients receiving opioid agonist medication for either heroin or pain pills were equally stigmatized and stigmatized more than hypothetical patients on nicotine agonist medication. Study 3 ( n = 151) showed that stigmatizing attitudes did not change as a result of enhanced treatment services for hypothetical MOUD patients (i.e. therapy as a supplement to medication). Conclusions/Importance : Results indicate that patients receiving agonist medication for an OUD may be the target of public stigma. Public education on the efficacy of agonist medications for OUD is urgently needed to help reduce such stigma, which may facilitate treatment delivery, treatment adherence, and treatment success. |
فهرسة مساهمة: | Keywords: Stigma; discrimination; medically assisted treatment; opioid agonist medication; opioid use disorder |
المشرفين على المادة: | 0 (Analgesics, Opioid) 40D3SCR4GZ (Buprenorphine) |
تواريخ الأحداث: | Date Created: 20210612 Date Completed: 20210802 Latest Revision: 20210802 |
رمز التحديث: | 20240628 |
DOI: | 10.1080/10826084.2021.1936051 |
PMID: | 34116605 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1532-2491 |
---|---|
DOI: | 10.1080/10826084.2021.1936051 |